- Home
- TSHA vs JANX Comparison
TSHA vs JANX Comparison
Compare TSHA & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- JANX
- Stock Information
- Founded
- TSHA 2019
- JANX 2017
- Country
- TSHA United States
- JANX United States
- Employees
- TSHA N/A
- JANX N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- TSHA Health Care
- JANX Health Care
- Exchange
- TSHA Nasdaq
- JANX Nasdaq
- Market Cap
- TSHA 1.4B
- JANX 1.4B
- IPO Year
- TSHA 2020
- JANX 2021
- Fundamental
- Price
- TSHA $4.72
- JANX $26.76
- Analyst Decision
- TSHA Strong Buy
- JANX Strong Buy
- Analyst Count
- TSHA 8
- JANX 11
- Target Price
- TSHA $9.63
- JANX $76.55
- AVG Volume (30 Days)
- TSHA 11.3M
- JANX 907.6K
- Earning Date
- TSHA 11-12-2025
- JANX 11-05-2025
- Dividend Yield
- TSHA N/A
- JANX N/A
- EPS Growth
- TSHA N/A
- JANX N/A
- EPS
- TSHA N/A
- JANX N/A
- Revenue
- TSHA $8,098,000.00
- JANX $439,000.00
- Revenue This Year
- TSHA N/A
- JANX N/A
- Revenue Next Year
- TSHA N/A
- JANX $91.66
- P/E Ratio
- TSHA N/A
- JANX N/A
- Revenue Growth
- TSHA N/A
- JANX N/A
- 52 Week Low
- TSHA $1.05
- JANX $21.73
- 52 Week High
- TSHA $5.51
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- TSHA 59.56
- JANX 56.60
- Support Level
- TSHA $4.80
- JANX $25.18
- Resistance Level
- TSHA $5.51
- JANX $29.09
- Average True Range (ATR)
- TSHA 0.44
- JANX 1.63
- MACD
- TSHA 0.04
- JANX 0.37
- Stochastic Oscillator
- TSHA 66.02
- JANX 59.29
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.